Tetrahydrocurcumin

Chemical Class	Reduced diarylheptanoid (hydrogenated curcuminoid metabolite)
Molecular Formula / CAS	C₂₁H₂₄O₆ · CAS 36062-04-1
Primary Botanical Source(s)	Turmeric (Curcuma longa)
Plant Part	Rhizome (as the metabolic reduction product of curcumin, or produced directly by chemical hydrogenation)
Typical Content	Not a major direct constituent of raw turmeric; primarily generated in the body as the principal metabolite of ingested curcumin, or manufactured by catalytic hydrogenation
Solubility / Format	Colourless, more chemically stable than curcumin; available as a high-purity standardised isolate powder
Sourcing Status	Product-live — genuine match via Herbuno’s turmeric extract line
Buy from Herbuno	Tetrahydrocurcumin 95% Powder (Turmeric)

Name origin: Tetrahydrocurcumin (THC) is named systematically for its structure — curcumin with four additional hydrogen atoms added across its two double bonds through reduction. Traditional use: Tetrahydrocurcumin was never used as an isolated traditional preparation; turmeric rhizome itself has millennia of documented use across Ayurvedic and broader South and Southeast Asian medicine and cuisine, with tetrahydrocurcumin only identified as a distinct compound once modern biochemistry traced curcumin’s metabolic fate in the body. Research trajectory: Interest in tetrahydrocurcumin grew directly out of curcumin bioavailability research: because ingested curcumin is poorly absorbed and rapidly metabolised, researchers investigating why turmeric’s traditional reputation exceeded curcumin’s modest measured blood levels identified tetrahydrocurcumin as curcumin’s major reduced metabolite, and, notably, found it retains — and in some assays exceeds — curcumin’s antioxidant potency while lacking some of curcumin’s pro-oxidant activity. Commercial source: Turmeric is the source plant for tetrahydrocurcumin, produced via chemical reduction of extracted curcuminoids, and Herbuno’s standardised extract reflects this well-established production route.

---

Evidence for Tetrahydrocurcumin Applications

Tetrahydrocurcumin is one of several reduced curcumin metabolites — alongside dihydro-, hexahydro- and octahydrocurcumin — that the body generates from ingested curcumin, and a review of these reductive metabolites found they retain diverse therapeutic effects including antioxidant, anticancer, anti-inflammatory and immunoregulatory activity, with tetrahydrocurcumin specifically noted for its free-radical-scavenging mechanism via cleavage at its active methylene group (et al. 2020). Claim strength: Moderate.

In streptozotocin-nicotinamide-induced diabetic rats, oral tetrahydrocurcumin administration (80 mg/kg body weight for 45 days) significantly increased plasma insulin and antioxidant levels (vitamin C, vitamin E, reduced glutathione) while decreasing lipid peroxidation, with the researchers reporting that THC’s antioxidant effects were superior to those achieved with equivalent curcumin treatment in the same study (Murugan & Pari 2007). This head-to-head comparison against curcumin is a notable and relatively unusual feature of the THC evidence base. Claim strength: Moderate.

A comprehensive 2025 review of tetrahydrocurcumin’s anticancer mechanisms describes it as modulating a wide range of oncogenic signalling networks, including NF-κB and activator protein-1 pathways and matrix metalloproteinase activity, combined with its established antioxidant and anti-inflammatory dual action; the reviewers characterise THC as a promising future anticancer therapeutic candidate, either as a standalone agent or as an adjuvant to established chemotherapy protocols, while noting translational and bioavailability challenges remain to be overcome (et al. 2025). Claim strength: Emerging.

Comparative cell-culture research examining curcumin, tetrahydrocurcumin and octahydrocurcumin side-by-side in LPS-stimulated macrophages found all three dose-dependently inhibited nitric oxide and MCP-1 production and NF-κB activation while upregulating Nrf2-dependent cytoprotective gene expression, indicating that anti-inflammatory and antioxidant activity is broadly retained across curcumin’s major reduced metabolites rather than being unique to the parent compound alone. All three compounds also inhibited phosphorylation of the p38 and ERK MAPK signalling proteins in the same study, though the relative potency ranking between curcumin and its metabolites varied depending on which specific inflammatory marker was measured. Claim strength: Moderate.

Formulators should note that tetrahydrocurcumin and curcumin are chemically and functionally distinct, despite the metabolic relationship between them: THC is colourless (lacking curcumin’s characteristic yellow pigment), generally more chemically stable, and exhibits a different balance of pro-oxidant versus antioxidant activity than curcumin. A product specification calling for “curcumin” content should not be assumed to deliver equivalent tetrahydrocurcumin exposure, and vice versa. Claim strength: High.

---

Dosage & Formulator Specification

Published animal research has used tetrahydrocurcumin doses around 80 mg/kg body weight over multi-week periods for antioxidant and antidiabetic effects; no formally established human clinical dosing range exists for isolated tetrahydrocurcumin specifically, distinct from the more extensive human dosing literature available for curcumin itself.

Analytical quantification of tetrahydrocurcumin is performed by HPLC; because it is chemically distinct from curcumin, demethoxycurcumin and bisdemethoxycurcumin (the three curcuminoids typically present in standard turmeric extract), formulators should request tetrahydrocurcumin-specific chromatographic data rather than a generic “curcuminoids” percentage.

Tetrahydrocurcumin’s greater chemical stability relative to curcumin (which is notably unstable under alkaline and light-exposed conditions) may offer formulation advantages in certain product types; formulators should still request stability data specific to their intended formulation base and shelf-life requirements rather than assuming stability improvements transfer uniformly across all matrices. This stability difference also has implications for finished-product appearance: because tetrahydrocurcumin lacks curcumin’s yellow pigment, formulations built around it will not carry the characteristic turmeric colour that some consumer-facing products intentionally use as a visual cue of potency.

Regulatory positioning for tetrahydrocurcumin follows established turmeric-derived-ingredient precedent in most markets, given turmeric’s long food and traditional-medicine use history; no tetrahydrocurcumin-specific regulatory limit exists. Formulators should avoid conflating tetrahydrocurcumin’s research base with curcumin’s more extensive human clinical trial literature when making product claims.

---

Frequently Asked Questions — Tetrahydrocurcumin

Related compounds: Curcumin, Licochalcone A